Member Exclusive

RNAi for hypercholesterolemia enters Phase III trial with NHS

The National Health Service (UK) has granted permission for Inclisiran, an RNAi drug developed by Alnylam Pharmaceuticals (MA, USA), to enter a Phase III clinical trial for cardiovascular disease.

Go to the profile of Alexander Marshall
Jan 14, 2020

Please sign in or register for FREE

No comments yet.